Abstract: Compounds of Formula (00A) and salts thereof, wherein R1, R2 R3, R4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Abstract: A lip-care lipstick with a repair effect relates to the technical field of daily necessities. The present invention aims to provide a lip-care lipstick with a repair effect. The lip-care lipstick includes the following components in parts by weight: 3-5 parts by weight of the Manuka honey containing the ME lip-care factor, 3-5 parts by weight of the royal jelly, 0.1-1 part of dipropylene glycol, 0.5-1.5 parts of allantoin, 22 parts by weight of the sodium hyaluronate, 15 parts by weight of polyglyceryl-2 diisostearate, 10 parts by weight of dipentaerythrityl hexahydroxystearate, 10 parts by weight of ethylhexyl palmitate, 8 parts by weight of tridecyl trimellitate, 5 parts by weight of avocado butter, 10 parts by weight of beeswax, 0.9 part by weight of tocopheryl acetate, 0.1 part by weight of methylparaben, 6 parts by weight of colorant and 5 parts by weight of other plant essential oils.

Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Abstract: A lip-care lipstick with antibacterial, anti-inflammatory and anti-oxidation effects relates to the technical field of daily necessities. The present invention aims to provide a lip-care lipstick with antibacterial, anti-inflammatory and anti-oxidation effects. The lip-care lipstick contains a Manuka honey active ingredient ME lip-care factor and plant medicinal extracts, which can repair and prevent the cracking and peeling of lips, promote the metabolism of tender skin, inhibit the inflammation of the lips and care the lip skin. The lip-care lipstick has a significant effect on the treatment of cheilitis. The lip-care lipstick includes the following components in parts by weight: 15-30 parts of Manuka honey containing the ME lip-care factor, 0.1-1 part of dipropylene glycol, 0.5-1.5 parts of allantoin, 47-50 parts of emollient, 3-15 parts of plant essential oil, 0.15-6.5 parts of colorant, 6 parts of thickener, 5 parts of binder and 6 parts of antioxidant.

Abstract: Disclosed herein are compounds (such as peptides or peptide mimetics) that bind to HIV RRE RNA. In some examples, the compounds inhibit (for example, decrease) binding of Rev to the RRE RNA. In some embodiments, the compounds include two moieties, each of which bind to one of the Rev binding sites in the RRE. In some examples, the moieties include peptides or small molecules. In some examples, the peptides include an arginine-rich motif. The RRE binding compounds may be further linked to a detectable label or cargo moiety. Also disclosed are methods of treating or inhibiting HIV including administering one or more of the disclosed compounds to a subject.

Abstract: Compounds of Formula (IA), or a pharmaceutically acceptable salt thereof, and methods of use as Janus kinase inhibitors are described herein.

Abstract: Triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R1a, R1b, R1c, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient.

Abstract: Compounds (such as peptides or peptide mimetics) that bind to HIV RRE RNA are provided. In some examples, the compounds inhibit (for example, decrease) binding of Rev to the RRE RNA. In some embodiments, the compounds include two moieties, each of which bind to one of the Rev binding sites in the RRE. In some examples, the moieties include peptides or small molecules. In some examples, the peptides include an arginine-rich motif. The RRE binding compounds may be further linked to a detectable label or cargo moiety. Also provided are methods of treating or inhibiting HIV including administering one or more of the RRE binding compounds to a subject.

Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

Abstract: The invention relates to a method for synthesizing a selectively labeled RNA, and an apparatus for performing the method. Specific segments or discrete residues within the RNA may be selectively labeled, and different segments may include different labels.

Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Abstract: A method for reducing fuel consumption of a work vehicle may include monitoring one or more loads associated with both a drive power requirement and a hydraulic power requirement for the work vehicle. In addition, the method may include actively adjusting one or more operating parameters of the work vehicle based on the monitored loads in a manner that meets the drive power requirement and the hydraulic power requirement for the work vehicle while reducing the fuel consumption of the vehicle's engine.

Abstract: Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.

Abstract: Compounds of Formula (I) and (II), or a stereoisomer, tautomer, solvate, prodrug or salt thereof, and methods of use as Janus kinase inhibitors are described herein.

Abstract: Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Abstract: Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.

Abstract: The invention relates to a method for synthesizing a selectively labeled RNA, and an apparatus for performing the method. Specific segments or discrete residues within the RNA may be selectively labeled, and different segments may include different labels.

Abstract: Compounds of Formula (I) and methods of use as Janus kinase inhibitors are described herein.

Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Abstract: Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.